The global protein A resins market size accounted for USD 1.50 billion in 2023 and is predicted to rake around USD 2.60 billion by 2033, growing at a CAGR of 5.65% from 2024 to 2033.
Key Points
- By region, North America led the protein A resins market with the largest market share of 42% in 2023.
- By region, Asia Pacific is expected to witness the fastest growth rate in the market during the forecast period.
- By application, the antibody purification segment dominated the protein A resins market in 2023 with market share of 60%.
- By product, the recombinant protein A segment had the largest share of around 58% in 20223.
- By matrix type, the agarose-based matrix segment dominated the market in 2023 with market share of 42.3%.
- By end-user, the pharmaceutical & biopharmaceutical companies segment dominated the market in 2023 with market share of 59%.
The protein A resins market plays a crucial role in the biopharmaceutical industry, providing essential purification tools for the production of therapeutic proteins. Protein A resins are widely used for the purification of monoclonal antibodies (mAbs) due to their high specificity and selectivity. As the demand for biopharmaceuticals continues to rise globally, driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology, the protein A resins market is poised for significant growth.
Get a Sample: https://www.precedenceresearch.com/sample/4063
Growth Factors:
Several factors contribute to the growth of the protein A resins market. The expanding biopharmaceutical industry, particularly in emerging markets such as Asia-Pacific and Latin America, is driving demand for protein A resins. Increasing investment in research and development by pharmaceutical companies and academic institutions is fueling innovation in biologics development, thereby boosting the demand for purification technologies like protein A resins.
Moreover, the growing adoption of monoclonal antibodies for the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases, is driving the demand for protein A resins. Monoclonal antibodies represent a rapidly expanding segment of the biopharmaceutical market, with numerous mAbs in clinical development and commercial use, creating a sustained demand for purification technologies.
Region Insights:
The protein A resins market exhibits regional variations driven by factors such as healthcare infrastructure, regulatory environment, and biopharmaceutical manufacturing capabilities.
In North America, the United States dominates the protein A resins market due to its robust biopharmaceutical industry, advanced healthcare infrastructure, and favorable regulatory environment. The presence of leading biopharmaceutical companies and academic research institutions drives innovation and demand for protein A resins in the region.
In Europe, countries like Germany, the United Kingdom, and Switzerland are key markets for protein A resins, owing to their strong biotechnology sectors and established pharmaceutical manufacturing facilities. The European Medicines Agency (EMA) plays a central role in regulating biopharmaceuticals, ensuring high-quality standards and safety, which bolsters demand for purification technologies like protein A resins.
In Asia-Pacific, countries such as China, India, and South Korea are experiencing rapid growth in the biopharmaceutical industry, driven by increasing healthcare expenditure, expanding middle-class population, and government initiatives to promote biotechnology innovation. The emergence of contract manufacturing organizations (CMOs) and biopharmaceutical clusters in the region is further fueling demand for protein A resins.
Protein A Resins Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 5.65% |
| Global Market Size in 2023 | USD 1.50 Billion |
| Global Market Size in 2024 | USD 1.58 Billion |
| Global Market Size by 2033 | USD 2.60 Billion |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Application, By Product, By Matrix Type, By End-user |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Protein A Resins Market Dynamics
Drivers:
Several drivers are propelling the growth of the protein A resins market. The increasing prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders, is driving demand for biopharmaceuticals, including monoclonal antibodies, which in turn fuels demand for protein A resins for purification.
Furthermore, advancements in biotechnology, such as the development of novel biologics and biosimilars, are expanding the applications of protein A resins. Biopharmaceutical companies are investing in research and development to create innovative therapies with improved efficacy and safety profiles, driving the adoption of protein A resins for downstream processing.
Additionally, the shift towards personalized medicine and targeted therapies is driving demand for monoclonal antibodies and other biologics, creating a favorable market environment for protein A resins. The ability of protein A resins to efficiently purify monoclonal antibodies from complex biological mixtures makes them indispensable tools in biopharmaceutical manufacturing.
Opportunities:
The protein A resins market presents several opportunities for growth and innovation. With the increasing demand for biopharmaceuticals worldwide, there is a growing need for high-performance purification technologies that can meet the stringent quality and regulatory requirements of the industry.
Furthermore, the emergence of new therapeutic modalities, such as cell and gene therapies, presents opportunities for the expansion of the protein A resins market. As these innovative therapies gain traction in the market, there is a growing demand for purification technologies capable of handling diverse types of biologics, including viral vectors, cell-based therapies, and gene editing products.
Moreover, the growing trend towards biosimilars and biobetters presents opportunities for protein A resin manufacturers to expand their product portfolios and capture new market segments. As more originator biologics face patent expiry, there is a growing market for biosimilar versions of these drugs, driving demand for purification technologies like protein A resins for their production.
Challenges:
Despite the promising growth prospects, the protein A resins market faces several challenges that could impact its trajectory. One such challenge is the high cost associated with protein A resins, which can limit their adoption, particularly in resource-constrained settings and emerging markets.
Moreover, the limited capacity and scalability of protein A resins production pose challenges for meeting the growing demand for biopharmaceuticals. Manufacturers are investing in process optimization and alternative purification technologies to address these challenges and enhance the efficiency and cost-effectiveness of downstream processing.
Furthermore, concerns regarding the leaching of protein A ligands and potential impurities in purified biologics represent regulatory and safety challenges for the protein A resins market. Manufacturers are continuously improving the design and performance of protein A resins to minimize leachables and ensure product safety and quality.
Read Also: Cosmetovigilance Market Size to Attain USD 17.60 Bn by 2033
Recent Developments
- In March 2024, Ultomiris received an approval from the United States for the long-term C5 complement inhibitor for the diagnostics of geriatric patients having anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder.
- In March 2024, Merck, a leading player in the life science technology company expanded its M LabTM Collaboration Center in Shanghai, China, it is the organization’s biggest in the global network of 10 interconnected labs. The investment worth € 14 million was added for the new biology application lab an upstream application lab and a process development training center to its M LabTM Collaboration Center in Shanghai.
- In April 2024, BioArctic AB collaborated with Eisai and announced the organization submitted the supplemental Biologics License Application (sBLA) for its drug Leqembi to the United States Food and Drug Administration (FDA).
- In April 2024, the US FDA approved and authorized the latest antibody drug named Pemgarda marketed by the biotech Invivyd, to protect immunocompromised individuals from COVID-19.
- In April 2024, Kemp Proteins LLC, a leading company in gene-to-protein services and monoclonal antibody development announced the strategic collaboration with the Columbia Biosciences of Frederick, Maryland.
- In April 2024, Sino Biological introduced a series of in vitro bioassay services for maintaining antibody drug development projects. Sino Biological offers different reagents and a range of n vitro efficacy evaluation services for meeting the demand for testing practices and trends.
Protein A Resins Market Companies
- GE Healthcare
- Merck Millipore
- PerkinElmer, Inc.
- GenScript Biotech Corp.
- Agilent Technologies
- Repligen Corp.
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories, Inc.
- Abcam PLC.
- Novasep Holdings SAS
Segments Covered in the Report
By Application
- Antibody purification
- Immunoprecipitation
By Product
- Recombinant protein A
- Natural protein A
By Matrix Type
- Agarose-based matrix
- Glass or silica gel-based matrix
- Organic polymer-based matrix
By End-user
- Pharmaceutical & Biopharmaceutical Companies
- Clinical research laboratories
- Academic research institutes
- Contract research organization
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
Blog: https://www.dailytechbulletin.com/
Blog: https://www.autoindustrybulletin.com/
